利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.058 秒)

    Imidazo[1,2-b]pyridazine compound
    22.
    发明授权
    Imidazo[1,2-b]pyridazine compound 失效
    咪唑并[1,2-b]哒嗪化合物

    公开(公告)号：US07772249B2

    公开(公告)日：2010-08-10

    申请号：US12397132

    申请日：2009-03-03

    申请人： Shigeki Hibi ,  Yoshinori Takahashi ,  Yorihisa Hoshino ,  Koichi Kikuchi ,  Motohiro Soejima ,  Tatsuya Yoshiuchi ,  Kogyoku Shin ,  Mutsuko Ono ,  Hisashi Shibata ,  Mitsuhiro Ino ,  Tetsuya Hirakawa

    发明人： Shigeki Hibi ,  Yoshinori Takahashi ,  Yorihisa Hoshino ,  Koichi Kikuchi ,  Motohiro Soejima ,  Tatsuya Yoshiuchi ,  Kogyoku Shin ,  Mutsuko Ono ,  Hisashi Shibata ,  Mitsuhiro Ino ,  Tetsuya Hirakawa

    IPC分类号： A61K31/44

    CPC分类号： C07D471/04 ,  C07D487/04

    摘要： The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof. Wherein R1 denotes a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group and the like; R2 denotes a halogen atom, a cyano group, a nitro group, a C1-10 alkyl group, a C2-10 alkenyl group, C2-10 alkynyl group and the like; R3 denotes a C6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR4 (wherein R4 denotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated C1-6 alkyl group and the like) and, in this case, at least two of X, Y and Z denote CR4.

    摘要翻译： 本发明提供具有优异的促肾上腺皮质激素释放因子受体拮抗活性的新型化合物。 也就是说，它提供由下式表示的化合物或其盐。 其中R1表示氢原子，C1-6烷基，C1-6烷氧基等; R2表示卤素原子，氰基，硝基，C1-10烷基，C2-10烯基，C2-10炔基等; R3表示可以具有取代基的C 6-14芳族烃环状基团或5〜14元芳香族杂环基团。 X，Y和X彼此独立地表示N或CR4（其中R4表示氢原子，卤素原子，氰基，硝基，任意卤代的C 1-6烷基等）和 在这种情况下，X，Y和Z中的至少两个表示CR 4。

    Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
    26.
    再颁专利
    Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes 失效
    嘌呤衍生物和腺苷A2受体拮抗剂作为糖尿病的预防药物/治疗药物

    公开(公告)号：USRE39112E1

    公开(公告)日：2006-05-30

    申请号：US11057854

    申请日：1998-12-24

    申请人： Osamu Asano ,  Hitoshi Harada ,  Yorihisa Hoshino ,  Seiji Yoshikawa ,  Takashi Inoue ,  Tatsuo Horizoe ,  Nobuyuki Yasuda ,  Kaya Ohashi ,  Junsaku Nagaoka ,  Manabu Murakami ,  Seiichi Kobayashi

    发明人： Osamu Asano ,  Hitoshi Harada ,  Yorihisa Hoshino ,  Seiji Yoshikawa ,  Takashi Inoue ,  Tatsuo Horizoe ,  Nobuyuki Yasuda ,  Kaya Ohashi ,  Junsaku Nagaoka ,  Manabu Murakami ,  Seiichi Kobayashi

    IPC分类号： C07D473/34 ,  C07D473/30 ,  C07D473/00 ,  A61K31/52 ,  A61K31/522

    CPC分类号： C07D473/30 ,  A61K31/52 ,  C07D473/00 ,  C07D473/34

    摘要： The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonist action.A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof has an adenosine A2 receptor antagonistic action and is useful for prevention or therapy of diabetes mellitus and diabetic complications. In addition, adenosine A2 receptor antagonists having different structures from those of the compounds described above, for example KW6002, are also effective for prevention or therapy of diabetes mellitus and diabetic complications. In the formula, W is —CH2CH2—, or —CH═CH— or —C≡C—; R1 is: (in the formula, X is hydrogen atom, hydroxyl group, a lower alkyl group, a lower alkoxy group, etc.; and R5 and R6 are the same as or different from each other and each represents hydrogen atom, a lower alkyl group, a cycloalkyl group, etc.) and the like; R2 is an amino group, etc. which maybe substituted with a lower alkyl group, etc.; R3 is a cycloalkyl group, an optionally substituted aryl group, etc.; and R4 is a lower alkyl group etc.

    摘要翻译： 本发明提供了基于腺苷A2受体拮抗剂作用的糖尿病新型糖尿病并发症的预防或治疗剂。 由式（I）表示的嘌呤化合物，其药理学上可接受的盐或其水合物具有腺苷A2受体拮抗作用，可用于预防或治疗糖尿病和糖尿病并发症。 此外，与上述化合物（例如KW6002）具有不同结构的腺苷A2受体拮抗剂对于糖尿病和糖尿病并发症的预防或治疗也是有效的。 在该式中，W是-CH 2 CH 2 - ，或-CH-CH-或-C≡C-; R 1是：（在该式中，X是氢原子，羟基，低级烷基，低级烷氧基等; R 5和R 5， SUP> 6 <！ - SIPO - >相同或不同，各自表示氢原子，低级烷基，环烷基等）等; R 2是可以被低级烷基等取代的氨基等; R 3是环烷基，任选取代的芳基等; R 4是低级烷基等。

    Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
    28.
    发明授权
    Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes 有权
    嘌呤衍生物和腺苷A2受体拮抗剂作为糖尿病的预防药物/治疗药物

    公开(公告)号：US06579868B1

    公开(公告)日：2003-06-17

    申请号：US09582840

    申请日：2000-07-05

    申请人： Osamu Asano ,  Hitoshi Harada ,  Yorihisa Hoshino ,  Seiji Yoshikawa ,  Takashi Inoue ,  Tatsuo Horizoe ,  Nobuyuki Yasuda ,  Kaya Nagata ,  Junsaku Nagaoka ,  Manabu Murakami ,  Seiichi Kobayashi

    发明人： Osamu Asano ,  Hitoshi Harada ,  Yorihisa Hoshino ,  Seiji Yoshikawa ,  Takashi Inoue ,  Tatsuo Horizoe ,  Nobuyuki Yasuda ,  Kaya Nagata ,  Junsaku Nagaoka ,  Manabu Murakami ,  Seiichi Kobayashi

    IPC分类号： C07D47334

    CPC分类号： C07D473/30 ,  A61K31/52 ,  C07D473/00 ,  C07D473/34

    摘要： The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonistic action. A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof has an adenosine A2 receptor antagonistic action and is useful for prevention or therapy of diabetes mellitus and diabetic complications. In addition, adenosine A2 receptor antagonists having different structures from those of the compounds described above, for example KW6002, are also effective for prevention or therapy of diabetes mellitus and diabetic complications. In the formula, W is —CH2CH2—, —CH═CH— or —C≡C—; R1 is: (in the formula, X is hydrogen atom, hydroxyl group, a lower alkyl group, a lower alkoxy group, etc.; and R5 and R6 are the same as or different from each other and each represents hydrogen atom, a lower alkyl group, a cycloalkyl group, etc.) and the like; R2 is an amino group, etc. which maybe substituted with a lower alkyl group, etc.; R3 is a cycloalkyl group, an optionally substituted aryl group, etc.; and R4 is a lower alkyl group etc.

    摘要翻译： 本发明提供了基于腺苷A2受体拮抗作用的新型糖尿病和糖尿病并发症的预防或治疗剂。由式（I）表示的嘌呤化合物，其药理学上可接受的盐或其水合物具有 腺苷A2受体拮抗作用，可用于预防或治疗糖尿病和糖尿病并发症。 此外，与上述化合物例如KW6002具有不同结构的腺苷A2受体拮抗剂对于预防或治疗糖尿病和糖尿病并发症也是有效的。在该式中，W是-CH 2 CH 2 - ， - CH = CH - 或-C = C-; R1为（式中，X为氢原子，羟基，低级烷基，低级烷氧基等），R5和R6彼此相同或不同，分别表示氢原子，低级 烷基，环烷基等）等; R2是可被低级烷基取代的氨基等; R3是环烷基，任选取代的芳基等; R4为低级烷基等。